Skip to contentO
Ovid Therapeutics Inc.
O
OVIDOvid Therapeutics Inc. Released Mar 7, 2019, after the close
10-K filed Mar 7, 2019, 66 days after period end · 0001564590-19-006804
Q4 2018 · 10-K
Revenue—
Net Income-$12.90M-$12.90MN/M vs Q4 2017N/M vs Q3 2018 EPS Diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
-$0.52-$0.52N/M vs Q4 2017N/M vs Q3 2018 Operating Incomederived-$13,116,348N/M Operating Cash Flowderived-$10,965,610N/M Free Cash Flowderived-$10,959,989N/M ended Dec 31, 2018 · filed Mar 7, 2019 · 66 d after period end